Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPH NASDAQ:CMPX NASDAQ:MLYS NYSE:RCUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$8.80-1.5%$8.07$5.20▼$10.67$1.19B1.161.41 million shs1.61 million shsCMPXCompass Therapeutics$2.70-5.3%$2.29$0.87▼$4.08$373.36M1.48975,345 shs1.01 million shsMLYSMineralys Therapeutics$14.49-1.0%$14.94$8.24▼$18.38$944.46M-0.3554,206 shs442,534 shsRCUSArcus Biosciences$9.35-2.0%$8.87$6.50▼$18.98$990.07M0.8883,406 shs545,958 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals+6.44%+18.03%+9.57%+20.51%+62.36%CMPXCompass Therapeutics+4.01%+2.70%+13.55%+68.14%+199.34%MLYSMineralys Therapeutics+1.88%+0.79%-8.67%+9.25%+11.76%RCUSArcus Biosciences+2.09%+12.29%-5.28%+17.56%-31.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPHAurinia Pharmaceuticals2.7962 of 5 stars3.51.00.00.02.60.81.9CMPXCompass Therapeutics2.6844 of 5 stars3.62.00.00.00.65.00.0MLYSMineralys Therapeutics2.4361 of 5 stars3.41.00.00.02.14.20.0RCUSArcus Biosciences2.952 of 5 stars4.43.00.00.01.21.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 3.00Buy$11.5030.68% UpsideCMPXCompass Therapeutics 3.10Buy$12.67369.14% UpsideMLYSMineralys Therapeutics 2.75Moderate Buy$32.25122.57% UpsideRCUSArcus Biosciences 2.89Moderate Buy$21.29127.65% UpsideCurrent Analyst Ratings BreakdownLatest CMPX, AUPH, MLYS, and RCUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025CMPXCompass TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform$9.006/17/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.006/10/2025MLYSMineralys TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$15.005/14/2025MLYSMineralys TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$48.005/13/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.005/9/2025CMPXCompass TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $10.005/9/2025RCUSArcus BiosciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $22.005/8/2025RCUSArcus BiosciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/7/2025RCUSArcus BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.005/7/2025RCUSArcus BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$29.00 ➝ $26.004/28/2025CMPXCompass TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$235.13M5.06$0.32 per share27.20$2.68 per share3.28CMPXCompass Therapeutics$850K439.25N/AN/A$0.91 per share2.97MLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/ARCUSArcus Biosciences$258M3.84N/AN/A$5.30 per share1.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals$5.75M$0.2831.4315.71N/A16.11%14.27%9.93%7/30/2025 (Estimated)CMPXCompass Therapeutics-$49.38M-$0.41N/AN/AN/AN/A-42.47%-38.31%8/11/2025 (Estimated)MLYSMineralys Therapeutics-$177.81M-$3.73N/AN/AN/AN/A-71.15%-65.71%8/12/2025 (Estimated)RCUSArcus Biosciences-$283M-$4.19N/AN/AN/A-258.94%-70.58%-32.97%8/4/2025 (Estimated)Latest CMPX, AUPH, MLYS, and RCUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025AUPHAurinia Pharmaceuticals$0.18N/AN/AN/A$64.27 millionN/A5/12/2025Q1 2025AUPHAurinia Pharmaceuticals$0.08$0.16+$0.08$0.16$61.06 million$62.47 million5/12/2025Q1 2025MLYSMineralys Therapeutics-$1.02-$0.79+$0.23-$0.79N/AN/A5/8/2025Q1 2025CMPXCompass Therapeutics-$0.12-$0.12N/A-$0.12N/AN/A5/6/2025Q1 2025RCUSArcus Biosciences-$1.02-$1.14-$0.12-$1.14$38.61 million$28.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/ACMPXCompass TherapeuticsN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.165.935.26CMPXCompass TherapeuticsN/A8.338.33MLYSMineralys TherapeuticsN/A26.4826.48RCUSArcus Biosciences0.095.375.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%CMPXCompass Therapeutics68.43%MLYSMineralys Therapeutics84.46%RCUSArcus Biosciences92.89%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals12.20%CMPXCompass Therapeutics29.80%MLYSMineralys Therapeutics25.56%RCUSArcus Biosciences9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300135.10 million118.62 millionOptionableCMPXCompass Therapeutics20138.28 million97.08 millionNot OptionableMLYSMineralys Therapeutics2865.18 million48.52 millionOptionableRCUSArcus Biosciences500105.89 million95.72 millionOptionableCMPX, AUPH, MLYS, and RCUS HeadlinesRecent News About These CompaniesArcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances5 hours ago | appliedclinicaltrialsonline.comAArcus’ Quemliclustat Receives Orphan Drug DesignationJuly 11 at 4:42 AM | contractpharma.comCArcus Biosciences' Pancreatic Cancer Treatment Gets Orphan Drug StatusJuly 11 at 4:42 AM | marketwatch.comArcus Biosciences’ Quemliclustat Receives Orphan Drug Designation for Pancreatic CancerJuly 11 at 4:42 AM | finance.yahoo.comArcus Biosciences (NYSE:RCUS) Shares Gap Up - Here's WhyJuly 10 at 11:09 AM | marketbeat.comArcus Biosciences' Quemliclustat Receives Orphan Drug Designation for Pancreatic CancerJuly 10 at 9:05 AM | gurufocus.comArcus Biosciences (NYSE:RCUS) Stock Price Up 8.1% - Should You Buy?July 9 at 6:28 PM | marketbeat.comArcus Biosciences Announces New Employment Inducement GrantsJuly 9 at 4:35 PM | businesswire.comArcus Biosciences (NYSE:RCUS) Trading Down 2.9% - Here's What HappenedJuly 3, 2025 | marketbeat.comArcus Biosciences Presents First Postive Data for Oral Metastatic Kidney Cancer TreatmentJuly 1, 2025 | msn.comArcus Biosciences (NYSE:RCUS) Trading Down 6.3% - Here's What HappenedJune 27, 2025 | marketbeat.comIncyte, FDA, Sun Pharma and more—Chutes & LaddersJune 27, 2025 | fiercebiotech.comFArcus Biosciences Announces New Employment Inducement Grants - Business WireJune 26, 2025 | businesswire.comPrecision Bio's DMD Therapy Gets Rare Pediatric Status, But Stock Slides; Retail Crowd Sees ‘Good Risk-Reward’June 26, 2025 | msn.comPrecision BioSciences Shares Surge Following FDA Rare Pediatric Disease DesignationJune 25, 2025 | msn.comPrecision BioSciences gets FDA rare disease status for DMD treatment, stock jumps 10%June 25, 2025 | msn.comArcus Biosciences, Inc. (RCUS) Cash Flow - Yahoo FinanceJune 24, 2025 | finance.yahoo.comRCUS Arcus Biosciences, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comArcus Biosciences Announces New Employment Inducement GrantsJune 24, 2025 | businesswire.comArcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of "Moderate Buy" by AnalystsJune 23, 2025 | marketbeat.comThe trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gambleJune 13, 2025 | fiercebiotech.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMPX, AUPH, MLYS, and RCUS Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$8.80 -0.13 (-1.46%) Closing price 04:00 PM EasternExtended Trading$8.80 -0.01 (-0.06%) As of 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Compass Therapeutics NASDAQ:CMPX$2.70 -0.15 (-5.26%) Closing price 04:00 PM EasternExtended Trading$2.73 +0.03 (+1.11%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Mineralys Therapeutics NASDAQ:MLYS$14.49 -0.15 (-1.02%) Closing price 04:00 PM EasternExtended Trading$14.49 0.00 (0.00%) As of 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Arcus Biosciences NYSE:RCUS$9.35 -0.19 (-1.99%) Closing price 03:59 PM EasternExtended Trading$9.24 -0.12 (-1.23%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
